Invitrogen™ CD11a Monoclonal Antibody (87-6F9)

Catalog No.	Quantity
01-676-898	100 μg

Catalog No. 01-676-898 Supplier Invitrogen™ Supplier No. MA135057

Description

Mouse Monoclonal Antibody

87-6F9 Reacts with CD11a, a transmembrane molecule with 1145 amino acid residues and a MW of 180 kDa. CD11a is expressed on lymphocytes, granulocytes, monocytes and macrophages. Levels on memory T-cells tend to increase. CD11a plays a key role in mediating leukocyte adhesion to endothelium during inflammatory response through binding to ICAM 1 (CD54). Other ligands are ICAM-2 and ICAM-3. It is also involved in many other T-cell functions and immune phenomena. When paired with CD18, it forms the integrin alphaLbeta2 adhesion. 87-6F9 Potently blocks LFA-1 dependent homotypic cell aggregation and was typed in the IVth International Leucocyte Typing Workshop.

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.

Specifications

• Antigen: CD11a
• Applications: Flow Cytometry, Immunohistochemistry (Frozen)
• Classification: Monoclonal
• Clone: 87-6F9
• Concentration: 100 μg/mL
• Conjugate: Unconjugated
• Formulation: PBS with 0.02% sodium azide
• Gene: ITGAL
• Gene Accession No.: P20701
• Gene Alias: (p180); alpha L integrin; antigen CD11A (p180); antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide; antigen CD11A p180; CD11 antigen-like family member A; CD11a; integrin alpha L; integrin alphaL; integrin alpha-L; integrin alpha-L precursor; integrin gene promoter; integrin subunit alpha L; integrin surface receptor; integrin, alpha L; integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide); ITGAL; Leukocyte adhesion glycoprotein LFA-1 alpha chain; leukocyte function-associated molecule 1 alpha chain; LFA-1; LFA-1 alpha; LFA1A; LFA-1A; Ly-15; Ly-21; lymphocyte antigen 15; lymphocyte function associated antigen 1, alpha polypeptide; lymphocyte function-associated antigen 1; lymphocyte function-associated antigen 1, alpha polypeptide; lymphocyte function-associated antigen-1
• Gene Symbols: ITGAL
• Host Species: Mouse
• Immunogen: Stimulated human leucocytes.
• Purification Method: purified
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 3683
• Target Species: Human
• Content And Storage: 4°C
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG2b

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov